As most of the EBV+ GCs that were analyzed in this study belong to tumor microenvironment type II, one could speculate whether the determination of the EBV status by the cost-intensive EBER in situ hybridization could be omitted in routine diagnostics, as those cases would be classified as type I by their CD8int high and positive PD-L1 expression, and thus would be most likely assigned to the category of tumors that benefit most from single-agent anti-PD-1/L1 therapy [16]. This evidence concerns the gene PDCD1 and neoplasm.